Schonfeld Strategic Advisors’s Epizyme, Inc EPZM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-18,600	Closed	-$28K	–	3377
2022 Q2	$28K	Sell	18,600 -1,900	-9%	-$1.4K	﹤0.01%	2281
2022 Q1	$23K	Buy	+20,500	New	+$33.4K	﹤0.01%	2391
2019 Q3	–	Sell	-260,900	Closed	-$3.27M	–	1319
2019 Q2	$3.27M	Sell	260,900 -155,700	-37%	-$2M	0.12%	207
2019 Q1	$5.16M	Buy	+416,600	New	+$4.66M	0.18%	151

Other funds holding EPZM

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Schonfeld Strategic Advisors's EPZM Position: Q3 2022 in Review

Schonfeld Strategic Advisors sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 18,600 shares — an estimated $28K sold.

Schonfeld Strategic Advisors first reported a position in EPZM in Q1 2019 and held it in 4 quarters. The position peaked at $5.16M in Q1 2019. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.

Schonfeld Strategic Advisors reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
Schonfeld Strategic Advisors sold 18,600 Epizyme, Inc shares in Q3 2022, an estimated $28K.
Schonfeld Strategic Advisors first reported a position in Epizyme, Inc in Q1 2019 and held it in 4 quarters.
Schonfeld Strategic Advisors's Epizyme, Inc position peaked at $5.16M in Q1 2019.
0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.